Literature DB >> 33472174

PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging.

Michael R Duggan1, Michael Weaver2, Kamel Khalili1.   

Abstract

Despite a growing proportion of aged individuals at risk for developing cancer in the brain, the prognosis for these conditions remains abnormally poor due to limited knowledge of underlying mechanisms and minimal treatment options. While cancer metabolism in other organs is commonly associated with upregulated glycolysis (i.e. Warburg effect) and hyperactivation of PIK3/AKT/mTOR (PAM) pathways, the unique bioenergetic demands of the central nervous system may interact with these oncogenic processes to promote tumor progression in aging. Specifically, constitutive glycolysis and PIK3/AKT/mTOR signaling in glia may be dysregulated by age-dependent alterations in neurometabolic demands, ultimately contributing to pathological processes otherwise associated with PIK3/AKT/mTOR induction (e.g. cell cycle entry, impaired autophagy, dysregulated inflammation). Although several limitations to this theoretical model exist, the consideration of aberrant PIK3/AKT/mTOR signaling in glia during aging elucidates several therapeutic opportunities for brain tumors, including non-pharmacological interventions.

Entities:  

Keywords:  aging; bioenergetics; glioma

Mesh:

Substances:

Year:  2021        PMID: 33472174      PMCID: PMC7835031          DOI: 10.18632/aging.202459

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  179 in total

1.  Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

Authors:  Michael C Schmid; Christie J Avraamides; Holly C Dippold; Irene Franco; Philippe Foubert; Lesley G Ellies; Lissette M Acevedo; Joan R E Manglicmot; Xiaodan Song; Wolfgang Wrasidlo; Sara L Blair; Mark H Ginsberg; David A Cheresh; Emilio Hirsch; Seth J Field; Judith A Varner
Journal:  Cancer Cell       Date:  2011-06-14       Impact factor: 31.743

Review 2.  Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.

Authors:  Hua Mao; Drake G Lebrun; Jingxuan Yang; Vivian F Zhu; Min Li
Journal:  Cancer Invest       Date:  2012-01       Impact factor: 2.176

3.  Insulin Regulates Astrocytic Glucose Handling Through Cooperation With IGF-I.

Authors:  Ana M Fernandez; Edwin Hernandez-Garzón; Paloma Perez-Domper; Alberto Perez-Alvarez; Sara Mederos; Takashi Matsui; Andrea Santi; Angel Trueba-Saiz; Lucía García-Guerra; Julia Pose-Utrilla; Jens Fielitz; Eric N Olson; Ruben Fernandez de la Rosa; Luis Garcia Garcia; Miguel Angel Pozo; Teresa Iglesias; Alfonso Araque; Hideaki Soya; Gertrudis Perea; Eduardo D Martin; Ignacio Torres Aleman
Journal:  Diabetes       Date:  2016-10-10       Impact factor: 9.461

4.  Does Alzheimer's disease protect against cancers? A nationwide population-based study.

Authors:  Shuo-Ming Ou; Yi-Jung Lee; Yu-Wen Hu; Chia-Jen Liu; Tzeng-Ji Chen; Jong-Ling Fuh; Shuu-Jiun Wang
Journal:  Neuroepidemiology       Date:  2012-10-11       Impact factor: 3.282

5.  Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence.

Authors:  Hei-Man Chow; Meng Shi; Aifang Cheng; Yuehong Gao; Guimiao Chen; Xuan Song; Raphaella Wai Lam So; Jie Zhang; Karl Herrup
Journal:  Nat Neurosci       Date:  2019-10-21       Impact factor: 24.884

Review 6.  Targeting RTK Signaling Pathways in Cancer.

Authors:  Tarik Regad
Journal:  Cancers (Basel)       Date:  2015-09-03       Impact factor: 6.639

Review 7.  Immunogenetics of glioblastoma: the future of personalized patient management.

Authors:  Malak Abedalthagafi; Duna Barakeh; Kara M Foshay
Journal:  NPJ Precis Oncol       Date:  2018-12-04

Review 8.  Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway.

Authors:  Sami Gabbouj; Simo Ryhänen; Mikael Marttinen; Rebekka Wittrahm; Mari Takalo; Susanna Kemppainen; Henna Martiskainen; Heikki Tanila; Annakaisa Haapasalo; Mikko Hiltunen; Teemu Natunen
Journal:  Front Neurosci       Date:  2019-06-18       Impact factor: 4.677

9.  The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype.

Authors:  Lucia Lisi; Emilia Laudati; Pierluigi Navarra; Cinzia Dello Russo
Journal:  J Neuroinflammation       Date:  2014-07-23       Impact factor: 8.322

Review 10.  Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence.

Authors:  Carmen Mecca; Ileana Giambanco; Rosario Donato; Cataldo Arcuri
Journal:  Dis Markers       Date:  2018-12-18       Impact factor: 3.434

View more
  3 in total

1.  Crowberry inhibits cell proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling in cholangiocarcinoma.

Authors:  Xue Wang; Xuebing Zhou; Ludan Zhang; Xin Zhang; Chunyu Yang; Yingshi Piao; Jinhua Zhao; Lili Jin; Guihua Jin; Renbo An; Xiangshan Ren
Journal:  Chin Med       Date:  2022-06-13       Impact factor: 4.546

2.  HAX1 maintains the glioma progression in hypoxia through promoting mitochondrial fission.

Authors:  Jinghui Lin; Yang Wang; Zhiqing Lin
Journal:  J Cell Mol Med       Date:  2021-11-10       Impact factor: 5.310

3.  Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma.

Authors:  Can Lu; Xi Chen; Yuanliang Yan; Xinxin Ren; Xiang Wang; Bi Peng; Yuan Cai; Qiuju Liang; Zhijie Xu; Jinwu Peng
Journal:  Front Pharmacol       Date:  2022-02-01       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.